Anavex Life Sciences Corp (AVXL)

[powerwalker]

Ladies and Gentlemen:

Anavex has not presented the 3 month or 9 month data separately. Those time periods have been presented only in conjunction with the 6 month and 12 month data, respectively. We should not expect 15 month data, though it would be great to see, until the 18 month data is ready. [The last participants to join should have reached the 18 month mark in early spring.]

As stated in this PR from March 2016:

NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.

Notice in the highlighted portion the words "new trial" which may be viewed that a new base line is being drawn for future evaluations.

Looking forward to the June and/or July presentation(s).